New acid blocker tested to make anesthesia safer

NCT ID NCT06743243

ENROLLING_BY_INVITATION Disease control Sponsor: Seok Kyeong Oh Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This study tests whether the drug tegoprazan can raise stomach acid levels before general anesthesia better than famotidine or a placebo. 174 adults having elective surgery will receive one of the three treatments an hour before anesthesia. The main goal is to measure stomach pH right after intubation, aiming to lower the risk of acid aspiration.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Tegoprazan
What this could lead to
If it works, tegoprazan could become a standard pre-anesthesia medication to reduce the risk of stomach acid entering the lungs during surgery.
What could go wrong
This is a small, early-phase trial focused on a lab measurement (gastric pH), not on actual complications. The drug may not show a meaningful benefit over existing options like famotidine.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GENERAL ANESTHESIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Korea University Medical Center, Guro Hospital

    Seoul, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.